{'fraction_non_alphanumeric': 0.027611044417767107, 'fraction_numerical': 0.013205282112845138, 'mean_word_length': 4.751724137931035, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Introduction: Adenosine A2A receptor modulation of motor systems for symptomatic therapy in Parkinson’s disease

The modern era of treatment for Parkinson’s disease (PD) began with the work of Cotzias et al.,1 who demonstrated that sustained improvement in the symptoms of the disease could be obtained by long-term therapy with l-dopa. Although l-dopa remains the most effective agent available for the management of PD, it was not long before the shortcomings of this approach became apparent. The most common problems are related to the development of “motor complications:” wearing off and dyskinesias. These are observed in at least 40% of patients with PD after 4 to 6 years of treatment with l-dopa and in up to 70% of patients after 10 years of treatment.2 With time, the magnitude of beneficial effect that can be achieved …